Possible antibiotic inactivation was studied in 12 subjects with end-stage renal disease who were undergoing thrice-weekly hemodialysis. The study was a randomized three-way crossover. Subjects received (i) gentamicin as a single intravenous dose of 2 mg/kg, (ii) 4 g of piperacillin intravenously every 12 h for four doses or 2 g of carbenicillin intravenously every 8 h for six doses, and (iii) gentamicin as described in (i) plus piperacillin or carbenicillin as described in (ii). Subjects were studied on their off-dialysis days, and each treatment phase was separated by a 3-week wash-out period. Gentamicin was inactivated to a greater extent by carbenicillin than by piperacillin (P < 0.05). In the six subjects in the carbenicillin group, the terminal elimination-phase half-life (t1/2p) of gentamicin was 61.6 h when gentamicin was administered alone, and it was 19.4 h when gentamicin was administered with carbenicillin. In six subjects in the piperacillin group, the mean t1/2p of gentamicin when gentamicin was given alone was 53.9 h, and it was 37.7 h when gentamicin was given with piperacillin. The inactivation rate constant (k,) of gentamicin was 0.0251/h for the carbenicillin group and 0.0064/h for the piperacillin group, demonstrating that carbenicillin inactivated gentamicin four times faster than did piperacillin. No inactivation of either ,3-lactam could be measured. Control samples verified that no in vitro inactivation occurred.
Piperacillin, a new semisynthetic penicillin, exhibits enhanced antimicrobial activity against many aerobic and anaerobic organisms and is an effective agent in the treatment of severe infections. It acts synergistically with the aminoglycosides against many strains of Pseudomonas aeruginosa and other gram-negative organisms in vitro (2, 6) . Combination therapy may therefore be useful in the treatment of severe infections. The value of this would be diminished, however, if piperacillin, like other penicillins, inactivates aminoglycosides in certain types of patients, such as those with renal failure (3, 11) .
Inactivation of aminoglycosides by piperacillin has been demonstrated in vitro (9) . In contrast, administration of piperacillin has not been observed to result in inactivation of aminoglycosides in subjects with normal renal function (W. H. Cannon, D. C. Hale, B. B. Gardner, and J. M. Matsen, unpublished data). This encouraged us to evaluate the inactivation of gentamicin when it was used in combination with piperacillin in subjects with chronic renal failure, compare the gentamicin-piperacillin combination with a carbenicillin-gentamicin combination, and determine whether these penicillins are inactivated by gentamicin. Since recent data reported by Pieper et al. (10) suggest that inactivation during the assay procedure may be responsible for previous reports of in vivo inactivation in patients with renal failure, it was necessary to distinguish in vitro from in vivo inactivation in renal failure patients during combination therapy. Therefore, sampling and analytical methods were used which allowed the determination of in vivo interactions.
MATERIALS AND METHODS
In vivo study. Twelve subjects with chronic renal failure who were stabilized on thrice-weekly intermittent hemodialysis were entered into the study. All subjects had a creatinine clearance of <5 ml/min and normal liver function.
The study used a randomized design, with each subject acting as his own control. Six subjects randomized to the piperacillin group received three separate treatments: piperacillin alone, gentamicin plus piperacillin, and gentamicin alone. The remaining six subjects, randomized to the carbenicillin group, received carbenicillin alone, carbenicillin plus gentamicin, and gentamicin alone. All treatment regimens for both groups were separated from one another by at least 3 weeks. All subjects were studied on their off-dialysis days.
Gentamicin Human serum (from a known donor) was spiked with gentamicin to a final concentration of 20 or 10 FLg/ml. The resulting samples were divided and placed into separate tubes, and piperacillin was added to a final concentration of 500 or 200 ,ug/ml. Piperacillin was not added to five tubes. The samples were then divided, and penicillinase was added to one half and cellulose phosphate powder to the other. Samples were processed as stated above and frozen at -70°C. Piperacillin samples were assayed at 72 h, and gentamicin samples were assayed at 10 and 14 days and 1 and 3 months. Previous in vitro studies verified that gentamicin is stable in the presence of carbenicillin when assayed by radioimmunoassay (RIA) (8) if frozen at -70°C. Carbenicillin is known to be stable upon freezing at -70°C for more than 10 days, and shows no loss of activity. (Pfizer Pharmaceuticals, personal communication.)
Assay method. Piperacillin levels were determined by a microbiological assay procedure modified as described by Bennett et al. (1) . The exact procedure has been described in detail pteviously (13) . Carbenicillin was assayed by a microbiological assay described by Sabath et al. (12) . Clostridium perfringens (UUMC 9758) was used as the test organism. An RIA technique (Science Monitor, Newport Beach, Calif.) was used to determine the gentamicin concentrations. In addition, gentamicin was assayed by a microbiological assay modified as described by Lund et al. (7) . Samples were assayed on a glass plate (30 by 30 cm) (1) penicillin activity. To inactivate 2,000 FJg of piperacillin per ml, 100,000 U of penicillinase was required. The addition of 200,000 U of penicillinase to gentamicin alone resulted in a 2% error in measuring gentamicin by RIA. No gentamicin could be measured when it had been added to 50 mg of cellulose phosphate powder.
In vitro controls, as determined by microbiological assay, demonstrated a loss of 60% of the gentamicin during storage and assay, but, when the controls were evaluated by RIA, no loss of activity was observed. Our results were similar to previously reported data (8) . For this reason, only gentamicin concentrations which were determined by RIA were used for pharmacokinetic analysis and are reported here.
Subject data. Data for subjects receiving carbenicillin were compared to data for subjects receiving piperacillin. Figure 1 is a graphic analysis of the mean (±standard deviation) gentamicin serum concentrations for each treatment group. The mean (±standard deviation) tl/2p of gentamicin when given alone was 61.6 ± 23.8 h for the carbenicillin group and 53.9 ± 7.4 h for the piperacillin group. This difference was not statistically significant (P > 0.10). Concurrent treatment with a penicillin significantly decreased the half-life in both treatment groups.
The tl/2p of gentamicin when used in combination with carbenicillin was 19.4 ± 4.9 h, as opposed to 37.7 ± 8.0 h (P < 0.05) for gentamicin used with piperacillin. A comparison of the two combinations showed the half-life of gentamicin to be significantly lower in the carbenicillin group than in the piperacillin group (P < 0.01). The mean decrease in the tl/2p of gentami- Tables 1 and 2 summarize the results of all treatment groups and the inactivation rate constants of gentamicin. Table 3 shows the carbenicillin/gentamicin and piperacillin/gentamicin serum concentration ratios at each time interval. Except for the 48-h sample, the carbenicillin/ gentamicin serum concentration ratios were similar or significantly lower than the piperacillin/ gentamicin serum concentration ratios. DISCUSSION Data from this study concerning the combination of carbenicillin and gentamicin are in accordance with previously published work (11, 14) . The ki of 0.025/h is similar to that reported by Ervin et al. (4) . In addition, piperacillin inactivated gentamicin. However, this in vivo inactivation was significantly less than that seen with carbenicillin. When gentamicin was given with carbenicillin, gentamicin concentrations decreased at four times the rate at which concentrations decreased when gentamicin was given with piperacillin. This is reflected in the carbenicillin/gentamicin serum concentration ratio at 48 h becoming significantly greater than the piperacillin/gentamicin ratio. Since piperacillin and carbenicillin inactivate gentamicin to a similar degree in vitro (9), the most likely reason for this in vivo difference is an increased rate of nonrenal elimination of piperacillin in renal failure patients (13) , thereby resulting in less contact time with gentamicin at high concentrations. Dosage adjustments of gentamicin may be required in renal failure patients receiving concurrent therapy with some penicillins. All 12 subjects receiving gentamicin alone had serum concentrations well above 2 gxg/ml at 48 h postdose. The mean concentration was 4.4 ± 0.8 ,ug/ ml. However, during combination therapy, four of six subjects receiving gentamicin and carbenicillin had gentamicin levels of <2 ,ug/ml by 41 h postdose. Therefore, supplemental doses of gentamicin, such as 1.0 to 1.5 mg/kg at 40 h postdose, may be necessary to maintain adequate concentrations before hemodialysis. Serum concentrations should be closely monitored to determine which patients require this and what their postdialysis dose should be. In contrast, only one of six subjects receiving gentamicin with piperacillin had gentamicin levels of <2 ,ug/ ml at 48 h.
No previous studies have evaluated the in vivo inactivation of penicillins given concurrently with an aminoglycoside. This is an important consideration, since both antibiotics are inactivated during the reaction, resulting in the apparent formation of an amide compound after cleavage of the 3-lactam ring of the penicillin by an amino group on the aminoglycoside. This product is microbiologically inactive (P. J. L. Daniels, Schering Corp., personal communication). In this study, no inactivation of either penicillin ANTIMICROB. AGENTS CHEMOTHER.
was found to take place in the presence of gentamicin. Since the reaction involves one molecule of an aminoglycoside binding to one molecule of a penicillin, a large concentration difference would prevent detection of the penicillin inactivation. For example, at a piperacillin or carbenicillin concentration of 200 ,ug/ml and a gentamicin concentration of 6 ,ug/ml, 100%o inactivation of the gentamicin would result in only 3% inactivation of the penicillin. The sensitivity of the assay procedure precludes detection of a 3% inactivation. This minimal effect would not be clinically significant.
The penicillin-aminoglycoside complex is known to be microbiologically inactive. However, the toxicity of the complex has not been evaluated. Weibert et al. reported that one patient in their study became deaf during prolonged gentamicin-carbenicillin therapy, even though the gentamicin level was <2 jxg/ml once carbenicillin therapy was started (14) . As long as the complex remains in the body, the possibility of tissue binding exists. Although serum levels reflect therapeutic concentrations, they do not measure the complex. Further studies are required to determine the significance and toxicity of these complexes.
